TARDBP and amyotrophic lateral sclerosis: The first example of drug screening in ALS hiPSC-derived MNs used cells from patients with TARDBP mutations that exhibited decreased neurite length, which allowed identification of anacardic acid (a histone acetyltransferase inhibitor) as a potential ALS therapeutic agent (Egawa et al., 2012).